ICOSL + plasmacytoid dendritic cells as inducer of graft-versus-host disease, responsive to a dual ICOS/CD28 antagonist

Djamilatou Adom,Stacey R Dillon,Jinfeng Yang,Hao Liu,Abdulraouf Ramadan,Kushi Kushekhar,Samantha Hund,Amanda Albright,Maykala Kirksey,Titilayo Adeniyan,Katherine E Lewis,Lawrence Evans,Rebecca Wu,Steven D Levin,Sherri Mudri,Jing Yang,Erika Rickel,Michelle Seaberg,Katherine Henderson,Chelsea J Gudgeon,Martin F Wolfson,Ryan M Swanson,Kristine M Swiderek,Stanford L Peng,Keli L Hippen,Bruce R Blazar,Sophie Paczesny,Stacey R. Dillon,Katherine E. Lewis,Steven D. Levin,Chelsea J. Gudgeon,Martin F. Wolfson,Ryan M. Swanson,Kristine M. Swiderek,Stanford L. Peng,Keli L. Hippen,Bruce R. Blazar
DOI: https://doi.org/10.1126/scitranslmed.aay4799
IF: 17.1
2020-10-07
Science Translational Medicine
Abstract:Intestinal CD146 + CCR5 + T cells activated by ICOSL + plasmacytoid DCs during acute GVHD can be inhibited by a dual ICOS/CD28 antagonist.
cell biology,medicine, research & experimental
What problem does this paper attempt to address?
The paper aims to address the issue of acute graft-versus-host disease (aGVHD), a major complication of allogeneic hematopoietic cell transplantation (HCT). Specifically, the paper explores the role of ICOS ligand (ICOSL) positive plasmacytoid dendritic cells (pDCs) in aGVHD and validates the potential of a dual ICOS/CD28 antagonist (ALPN-101) in the prevention and treatment of aGVHD. Key findings of the paper include: - In patients with gastrointestinal aGVHD, the frequency of ICOSL+ pDCs increases and correlates with the frequency of CD146+CCR5+ T cells. - In mouse models, donor bone marrow cells from ICOSL-deficient mice reduced aGVHD-related mortality compared to those from wild-type mice. - In immunodeficient mouse models, transplantation of activated human ICOSL+ pDCs led to the infiltration of CD146+CCR5+ T cells in the gut. - The dual ICOS/CD28 antagonist ALPN-101 was more effective in preventing aGVHD than the existing drug belatacept, and starting treatment at the onset of symptoms also alleviated aGVHD symptoms and improved survival rates while preserving anti-tumor cytotoxicity. In summary, the paper supports the role of ICOSL+ pDCs as biomarkers for aGVHD through experimental data and suggests that inhibiting the ICOSL/ICOS and B7/CD28 pathways could be a new strategy for the prevention or treatment of aGVHD.